Hjem › Myasthenia gravis › Ohio
Myasthenia gravis kliniske forsøg i Ohio
13 studier for Myasthenia gravis søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0038 10103, Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07463521ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- University of Cincinnati Medical Center - Goodman St, Cincinnati
- Ohio State Martha Morehouse Outpatient Care, Columbus
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT07294170A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0039 10103, Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT07465289ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- University of Cincinnati Medical Center - Goodman St, Cincinnati
- Ohio State Martha Morehouse Outpatient Care, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT07284420Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Miami Valley Hospital South, Centerville
- University of Cincinnati, Cincinnati
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT06463587A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, Cleveland
- TG Therapeutics Investigational Trial Site, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06680037Zilucoplan for Severe gMG Exacerbations
- The Ohio State University, Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07215949Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- The Ohio State University, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06414954Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1038, Cincinnati
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 30. jul. 2026 · NCT07039916A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Cleveland Clinic, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT04951622A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- University of Cincinnati Health Physicians - Clifton, Cincinnati
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. jun. 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Ohio State University, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. feb. 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Dayton
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 18. feb. 2026 · NCT04202341Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.